Immunological modification of adriamycin cardiotoxicity

Adriamycin-specific antibody has been shown to increase the survival of mice receiving an acute cardiotoxic dose of adriamycin. The concentrations of adriamycin in heart tissue were reduced and those in tumor elevated for more than 2 days in animals that received the antibody. The adriamycin-specific antibody prevented and reversed adriamycin inhibition of cardiac microsomal Na-K ATPase

Fluoroscopically guided thin needle aspiration biopsy of the abdomen and retroperitoneum

The results of 49 transabdominal and translumbar thin needle percutaneous aspiration biopsies in patients suspected of having malignant disease are reported. A correct diagnosis was obtained in 40 cases. Placement of the Chiba needle was accomplished by fluoroscopically controlled biplane radiography during constrast examinations. No complications were encountered. The technique allows cytologic diagnosis of malignancy without high risk exploratory surgery, prolonged hospitalization, or delay of treatment. Use of fluoroscopic needle guidance and biplane radiography for confirmation of position using various contrast examinations as markers is felt to be superior to either CT or ultrasound. The technique is readily available in all radiology departments

Chemotherapy of the Transplantable Adenocarcinoma (R-3327) of the Copenhagen Rat

A number of therapeutic agents including L-asparaginase, Actinomycin-D, CCNU, Hydroxyurea, 5-FU, Cis-platinum, Cyclophosphamide, orchiectomy, Adriamycin and DES alone and in various combinations has been applied against the Dunning R-3327 rat prostatic adenocarcinoma subline G. We have found a parallel between the results of this study and those of similar therapeutic application to the human tumor. We conclude that this animal model may prove to be a useful screening system for agents against human prostatic cancer

Randomized phase II clinical trial of adriamycin, methotrexate, and actinomycin-D in advanced measurable pancreatic carcinoma: a Gastrointestinal Tumor Study Group Report

Sixty-six patients with advanced pancreatic carcinoma were randomized to receive single agent chemotherapy with either adriamycin, methotrexate, or actinomycin-D using conventional dose, route and schedule of administration. All patients had measurable lesions which were used to objective assessment of response. For adriamycin, 2 of 25 patients (8%) evidenced a partial response (2 of 15 (13%) previously untreated patients). One of 25 patients treated with methotrexate and one of 28 received actinomycin-D responded. The duration of responses ranged from 43-64 days for those patients with no chemotherapy prior to study entry. The median survival of patients who received adriamycin as initial treatment was 12 weeks compared to 8 weeks for methotrexate and 6 weeks for actinomycin-D therapy